Galena Biopharma, Inc.

Vifor Pharma Group is hopeful that its hyperkalemia therapy Veltassa, which enjoyed strong sales growth in 2019, will be able to fend off competition from AstraZeneca PLC 's rival treatment Lokelma.

Galenica 's Verfora consumer health division took top spot in the Swiss market for the first time last year, propelled by strong growth from its leading OTC brands. “Verfora became the number-one comp

After announcing its first full-year results as a standalone company, Vifor Pharma Group has laid out ambitious growth plans to more than double sales by 2020, driven by two potential blockbusters –

Financings Third-quarter 2017 biopharma financing reached $12.5 billion, just a 6% decrease from the previous quarter's $13.4 billion. ( See Exhibit 1. ) The most money was raised in the follow-on pub